10x Genomics (TXG) Stock Price, News & Analysis

Company Overview

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Key Stats

• Today's Range: $19.95 to $20.83
• 50-Day Range: $18.13 to $23.49
• 52-Week Range: $15.28 to $57.90
• Volume: 1.46 million shs
• Average Volume: 1.61 million shs
• Market Capitalization: $2.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $31.60
• Consensus Rating: Moderate Buy

10x Genomics Stock Analysis - MarketRank™

10x Genomics scored higher than 96% of companies evaluated by MarketBeat, and ranked 54th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

10x Genomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 7 buy ratings, 7 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

10x Genomics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for 10x Genomics are expected to grow in the coming year, from ($1.32) to ($0.87) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of 10x Genomics is -9.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 10x Genomics is -9.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

10x Genomics has a P/B Ratio of 3.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.48% of the outstanding shares of 10x Genomics have been sold short.

Short Interest Ratio / Days to Cover

10x Genomics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in 10x Genomics has recently decreased by 12.64%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

10x Genomics does not currently pay a dividend.

Dividend Growth

10x Genomics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.8 / 5
• Environmental Score: -0.73

Percentage of Shares Shorted

6.48% of the outstanding shares of 10x Genomics have been sold short.

Short Interest Ratio / Days to Cover

10x Genomics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in 10x Genomics has recently decreased by 12.64%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.55

News Sentiment

10x Genomics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for 10x Genomics this week, compared to 5 articles on an average week.

Search Interest

Only 9 people have searched for TXG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

12 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $316,794.00 in company stock.

Percentage Held by Insiders

10.03% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TXG Stock Analysis - Frequently Asked Questions

How have TXG shares performed this year?

10x Genomics' stock was trading at $55.96 at the start of the year. Since then, TXG shares have decreased by 62.8% and is now trading at $20.81.
View the best growth stocks for 2024 here.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.15. The business earned $153.10 million during the quarter, compared to analyst estimates of $150.90 million. 10x Genomics had a negative trailing twelve-month return on equity of 28.23% and a negative net margin of 37.90%.

When did 10x Genomics IPO?

10x Genomics (TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

10x Genomics' top institutional shareholders include Mirador Capital Partners LP (0.05%), Handelsbanken Fonder AB (0.02%), SG Americas Securities LLC (0.02%) and CWM LLC (0.02%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Mathai Mammen, Justin J Mcanear, James Wilbur, Sridhar Kosaraju and Bradford Crutchfield.
View institutional ownership trends.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 8/08/2024
• Today: 10/09/2024
• Next Earnings (Estimated): 11/07/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TXG
• CUSIP: N/A
• CIK: 1770787
• Web: www.10xgenomics.com
• Phone: 925-401-7300
• Fax: N/A
• Employees: 1,259
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $31.60
• High Stock Price Target: $60.00
• Low Stock Price Target: $16.00
• Potential Upside/Downside: +51.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 16 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-255,100,000.00
• Net Margins: -37.90%
• Pretax Margin: -36.92%
• Return on Equity: -28.23%
• Return on Assets: -21.95%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.22
• Quick Ratio: 4.42

Sales & Book Value

• Annual Sales: $618.73 million
• Price / Sales: 4.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.22 per share
• Price / Book: 3.35

Miscellaneous

• Outstanding Shares: 120,490,000
• Free Float: 107,215,000
• Market Cap: $2.51 billion
• Optionable: Optionable
• Beta: 1.85